Skip to main content
Top
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Hypertension | Research

Higher plasma aldosterone concentrations in patients with aortic diseases and hypertension: a retrospective observational study

Authors: Yuting Pu, Guifang Yang, Xiaogao Pan, Yang Zhou, Aifang Zhong, Ning Ding, Yingjie Su, Wen Peng, Mengping Zeng, Tuo Guo, Xiangping Chai

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Aortic diseases remain a highly perilous macrovascular condition. The relationship between circulating aldosterone and aortic diseases is rarely explored, thus we investigated the difference in plasma aldosterone concentration (PAC) between patients with and without aortic disease in hypertensive people.

Methods

We analyzed 926 patients with hypertension, ranging in age from 18 to 89 years, who had their PAC measured from the hospital's electronic database. The case group and control group were defined based on inclusion and exclusion criteria. The analysis included general information, clinical data, biochemical data, and medical imaging examination results as covariates. To further evaluate the difference in PAC between primary hypertension patients with aortic disease and those without, we used multivariate logistic regression analysis and also employed propensity score matching to minimize the influence of confounding factors.

Results

In total, 394 participants were included in the analysis, with 66 individuals diagnosed with aortic diseases and 328 in the control group. The participants were predominantly male (64.5%) and over the age of 50 (68.5%), with an average PAC of 19.95 ng/dL. After controlling for confounding factors, the results showed hypertension patients with aortic disease were more likely to have high PAC levels than those without aortic disease (OR = 1.138, 95% CI [1.062 to 1.238]). Subgroup analysis revealed consistent relationship between PAC and primary hypertensive patients with aortic disease across the different stratification variables. Additionally, hypertensive patients with aortic disease still have a risk of higher PAC levels than those without aortic disease, even after propensity score matching.

Conclusions

The results of this study suggest that primary hypertensive patients with aortic diseases have elevated levels of PAC, but the causal relationship between PAC and aortic disease requires further study.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. Nat Rev Cardiol. 2021;18(5):331–48.PubMedCrossRef Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. Nat Rev Cardiol. 2021;18(5):331–48.PubMedCrossRef
2.
go back to reference Erbel R, et al. Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873–926.PubMedCrossRef Erbel R, et al. Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873–926.PubMedCrossRef
3.
go back to reference Evangelista A, et al. Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research. Circulation. 2018;137(17):1846–60.PubMedCrossRef Evangelista A, et al. Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research. Circulation. 2018;137(17):1846–60.PubMedCrossRef
4.
go back to reference Huang X, et al. Projection of global burden and risk factors for aortic aneurysm–timely warning for greater emphasis on managing blood pressure. Ann Med. 2022;54(1):553–64.PubMedPubMedCentralCrossRef Huang X, et al. Projection of global burden and risk factors for aortic aneurysm–timely warning for greater emphasis on managing blood pressure. Ann Med. 2022;54(1):553–64.PubMedPubMedCentralCrossRef
6.
go back to reference Epstein M, et al. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am J Kidney Dis. 2022;80(5):658–66.PubMedCrossRef Epstein M, et al. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am J Kidney Dis. 2022;80(5):658–66.PubMedCrossRef
7.
go back to reference Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res. 2023;119(1):28–44.PubMedCrossRef Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res. 2023;119(1):28–44.PubMedCrossRef
8.
go back to reference Gorini S, et al. Role of aldosterone and mineralocorticoid receptor in cardiovascular aging. Front Endocrinol (Lausanne). 2019;10:584.PubMedCrossRef Gorini S, et al. Role of aldosterone and mineralocorticoid receptor in cardiovascular aging. Front Endocrinol (Lausanne). 2019;10:584.PubMedCrossRef
9.
10.
go back to reference Belden Z, et al. The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature. Am J Nephrol. 2017;46(4):298–314.PubMedCrossRef Belden Z, et al. The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature. Am J Nephrol. 2017;46(4):298–314.PubMedCrossRef
11.
go back to reference Liu S, et al. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arterioscler Thromb Vasc Biol. 2013;33(7):1568–79.PubMedPubMedCentralCrossRef Liu S, et al. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arterioscler Thromb Vasc Biol. 2013;33(7):1568–79.PubMedPubMedCentralCrossRef
12.
go back to reference Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Kardiol Pol. 2014;72(12):1169–252.PubMedCrossRef Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Kardiol Pol. 2014;72(12):1169–252.PubMedCrossRef
13.
go back to reference Zhang Z. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med. 2016;4(2):30.PubMedPubMedCentral Zhang Z. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med. 2016;4(2):30.PubMedPubMedCentral
14.
go back to reference Ebrahimi Kalan M, et al. Distinction between two statistical terms: multivariable and multivariate logistic regression. Nicotine Tob Res. 2021;23(8):1446–7.PubMedCrossRef Ebrahimi Kalan M, et al. Distinction between two statistical terms: multivariable and multivariate logistic regression. Nicotine Tob Res. 2021;23(8):1446–7.PubMedCrossRef
15.
go back to reference Liang J, et al. Using propensity score matching to balance the baseline characteristics. J Thorac Oncol. 2021;16(6):e45–6.PubMedCrossRef Liang J, et al. Using propensity score matching to balance the baseline characteristics. J Thorac Oncol. 2021;16(6):e45–6.PubMedCrossRef
16.
go back to reference Huckaby LV, et al. Sex-based aortic dissection outcomes from the international registry of acute aortic dissection. Ann Thorac Surg. 2022;113(2):498–505.PubMedCrossRef Huckaby LV, et al. Sex-based aortic dissection outcomes from the international registry of acute aortic dissection. Ann Thorac Surg. 2022;113(2):498–505.PubMedCrossRef
17.
go back to reference Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261–73.PubMedCrossRef Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261–73.PubMedCrossRef
18.
go back to reference Ferreira NS, et al. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34(1):15–27.PubMedCrossRef Ferreira NS, et al. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34(1):15–27.PubMedCrossRef
19.
go back to reference Te Riet L, et al. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960–75.CrossRef Te Riet L, et al. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960–75.CrossRef
20.
go back to reference Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res. 2021;82(3):341–63.PubMedCrossRef Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res. 2021;82(3):341–63.PubMedCrossRef
21.
go back to reference Rafiq K, et al. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci. 2011;115(1):1–7.PubMedCrossRef Rafiq K, et al. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci. 2011;115(1):1–7.PubMedCrossRef
23.
go back to reference Catena C, Colussi G, Sechi LA. Aldosterone, organ damage and dietary salt. Clin Exp Pharmacol Physiol. 2013;40(12):922–8.PubMedCrossRef Catena C, Colussi G, Sechi LA. Aldosterone, organ damage and dietary salt. Clin Exp Pharmacol Physiol. 2013;40(12):922–8.PubMedCrossRef
24.
go back to reference Yang K, et al. Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype. Eur Heart J. 2020;41(26):2442–53.PubMedCrossRef Yang K, et al. Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype. Eur Heart J. 2020;41(26):2442–53.PubMedCrossRef
25.
go back to reference Gawinecka J, Schönrath F, von Eckardstein A. Acute aortic dissection: pathogenesis, risk factors and diagnosis. Swiss Med Wkly. 2017;147: w14489.PubMed Gawinecka J, Schönrath F, von Eckardstein A. Acute aortic dissection: pathogenesis, risk factors and diagnosis. Swiss Med Wkly. 2017;147: w14489.PubMed
26.
go back to reference Xie X, et al. Mineralocorticoid receptor deficiency improves the therapeutic effects of mesenchymal stem cells for myocardial infarction via enhanced cell survival. J Cell Mol Med. 2019;23(2):1246–56.PubMedCrossRef Xie X, et al. Mineralocorticoid receptor deficiency improves the therapeutic effects of mesenchymal stem cells for myocardial infarction via enhanced cell survival. J Cell Mol Med. 2019;23(2):1246–56.PubMedCrossRef
27.
go back to reference Young MJ, Rickard AJ. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol. 2015;224(1):R1-13.PubMedCrossRef Young MJ, Rickard AJ. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol. 2015;224(1):R1-13.PubMedCrossRef
28.
go back to reference Mihailidou AS, Tzakos AG, Ashton AW. Non-genomic effects of aldosterone. Vitam Horm. 2019;109:133–49.PubMedCrossRef Mihailidou AS, Tzakos AG, Ashton AW. Non-genomic effects of aldosterone. Vitam Horm. 2019;109:133–49.PubMedCrossRef
29.
go back to reference Ashton AW, et al. Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury. Mol Endocrinol. 2015;29(8):1144–55.PubMedPubMedCentralCrossRef Ashton AW, et al. Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury. Mol Endocrinol. 2015;29(8):1144–55.PubMedPubMedCentralCrossRef
30.
go back to reference Stroedecke K, et al. The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy. Sci Rep. 2021;11(1):13229.PubMedPubMedCentralCrossRef Stroedecke K, et al. The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy. Sci Rep. 2021;11(1):13229.PubMedPubMedCentralCrossRef
31.
go back to reference Li X, et al. G protein-coupled estrogen receptor: a promising therapeutic target for aldosterone-induced hypertension. Front Endocrinol (Lausanne). 2023;14:1226458.PubMedCrossRef Li X, et al. G protein-coupled estrogen receptor: a promising therapeutic target for aldosterone-induced hypertension. Front Endocrinol (Lausanne). 2023;14:1226458.PubMedCrossRef
32.
go back to reference Maning J, et al. Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy. Pharmacol Res. 2017;125(Pt A):14–20.PubMedCrossRef Maning J, et al. Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy. Pharmacol Res. 2017;125(Pt A):14–20.PubMedCrossRef
33.
go back to reference Montiel-Jaen MG, Monsalvo-Villegas A, Ávila G. Modulating ALDH2 reveals a differential dependence on ROS for hypertrophy and SR Ca(2+) release in aldosterone-treated cardiac myocytes. Biochem Biophys Res Commun. 2021;536:7–13.PubMedCrossRef Montiel-Jaen MG, Monsalvo-Villegas A, Ávila G. Modulating ALDH2 reveals a differential dependence on ROS for hypertrophy and SR Ca(2+) release in aldosterone-treated cardiac myocytes. Biochem Biophys Res Commun. 2021;536:7–13.PubMedCrossRef
34.
go back to reference Brem AS, Gong R. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease. Clin Sci (Lond). 2015;128(9):527–35.PubMedCrossRef Brem AS, Gong R. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease. Clin Sci (Lond). 2015;128(9):527–35.PubMedCrossRef
35.
go back to reference Muehlfelder M, et al. Both estrogen receptor subtypes, ERα and ERβ, prevent aldosterone-induced oxidative stress in VSMC via increased NADPH bioavailability. Biochem Biophys Res Commun. 2012;423(4):850–6.PubMedCrossRef Muehlfelder M, et al. Both estrogen receptor subtypes, ERα and ERβ, prevent aldosterone-induced oxidative stress in VSMC via increased NADPH bioavailability. Biochem Biophys Res Commun. 2012;423(4):850–6.PubMedCrossRef
36.
go back to reference Hao J, et al. MicroRNA-34b/c inhibits aldosterone-induced vascular smooth muscle cell calcification via a SATB2/Runx2 pathway. Cell Tissue Res. 2016;366(3):733–46.PubMedCrossRef Hao J, et al. MicroRNA-34b/c inhibits aldosterone-induced vascular smooth muscle cell calcification via a SATB2/Runx2 pathway. Cell Tissue Res. 2016;366(3):733–46.PubMedCrossRef
37.
go back to reference Maning J, et al. Antagonistic roles of GRK2 and GRK5 in cardiac aldosterone signaling reveal GRK5-mediated cardioprotection via mineralocorticoid receptor inhibition. Int J Mol Sci. 2020;21(8):2868.PubMedPubMedCentralCrossRef Maning J, et al. Antagonistic roles of GRK2 and GRK5 in cardiac aldosterone signaling reveal GRK5-mediated cardioprotection via mineralocorticoid receptor inhibition. Int J Mol Sci. 2020;21(8):2868.PubMedPubMedCentralCrossRef
38.
go back to reference Zhang J, et al. Inhibitory effect of CP-25 on intimal formation and vascular hyperplasia via suppression of GRK2/ERK1/2/EVI1 signaling. Arch Biochem Biophys. 2020;694: 108601.PubMedCrossRef Zhang J, et al. Inhibitory effect of CP-25 on intimal formation and vascular hyperplasia via suppression of GRK2/ERK1/2/EVI1 signaling. Arch Biochem Biophys. 2020;694: 108601.PubMedCrossRef
39.
go back to reference Ohno Y, et al. Nadir aldosterone levels after confirmatory tests are correlated with left ventricular hypertrophy in primary aldosteronism. Hypertension. 2020;75(6):1475–82.PubMedCrossRef Ohno Y, et al. Nadir aldosterone levels after confirmatory tests are correlated with left ventricular hypertrophy in primary aldosteronism. Hypertension. 2020;75(6):1475–82.PubMedCrossRef
40.
41.
go back to reference Chou CH, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res. 2018;114(5):690–702.PubMedCrossRef Chou CH, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res. 2018;114(5):690–702.PubMedCrossRef
42.
go back to reference Jia G, et al. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72(3):537–48.PubMedCrossRef Jia G, et al. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72(3):537–48.PubMedCrossRef
43.
go back to reference Zhu Q, et al. Higher plasma aldosterone concentrations are associated with elevated risk of aortic dissection and aneurysm: a case-control study. Hypertension. 2022;79(4):736–46.PubMedCrossRef Zhu Q, et al. Higher plasma aldosterone concentrations are associated with elevated risk of aortic dissection and aneurysm: a case-control study. Hypertension. 2022;79(4):736–46.PubMedCrossRef
44.
go back to reference Zhang Y, et al. Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review. BMC Endocr Disord. 2020;20(1):115.PubMedPubMedCentralCrossRef Zhang Y, et al. Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review. BMC Endocr Disord. 2020;20(1):115.PubMedPubMedCentralCrossRef
45.
go back to reference Jin HY, Lee KA. Primary hyperaldosteronism: a rare cause of acute aortic dissection. Korean J Intern Med. 2021;36(2):477–8.PubMedCrossRef Jin HY, Lee KA. Primary hyperaldosteronism: a rare cause of acute aortic dissection. Korean J Intern Med. 2021;36(2):477–8.PubMedCrossRef
46.
go back to reference Ferraino KE, et al. Adrenal angiotensin II type 1 receptor biased signaling: the case for “biased” inverse agonism for effective aldosterone suppression. Cell Signal. 2021;82: 109967.PubMedCrossRef Ferraino KE, et al. Adrenal angiotensin II type 1 receptor biased signaling: the case for “biased” inverse agonism for effective aldosterone suppression. Cell Signal. 2021;82: 109967.PubMedCrossRef
Metadata
Title
Higher plasma aldosterone concentrations in patients with aortic diseases and hypertension: a retrospective observational study
Authors
Yuting Pu
Guifang Yang
Xiaogao Pan
Yang Zhou
Aifang Zhong
Ning Ding
Yingjie Su
Wen Peng
Mengping Zeng
Tuo Guo
Xiangping Chai
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01528-2

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue